Fase 3-undersøgelse af supplerende behandling med Seltorexant hos voksne og ældre deltagere med svær depressiv lidelse og søvnløshedssymptomer
En todelt multicenter, dobbeltblind, randomiseret placebokontrolleret undersøgelse til evaluering af effektivitet og sikkerhed og opretholdelse af effekten af 20-(milligram) mg Seltorexant som supplerende terapi til antidepressiva hos voksne og ældre patienter med svær depressiv lidelse med søvnløshedssymptomer
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1133AAH
- Aktiv, ikke rekrutterende
- Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
-
Córdoba, Argentina, 5000FJF
- Aktiv, ikke rekrutterende
- CEN Consultorios Especializados en Neurociencias
-
Córdoba, Argentina, X5003DCE
- Aktiv, ikke rekrutterende
- Instituto Medico DAMIC
-
Córdoba, Argentina, X5006CBI
- Aktiv, ikke rekrutterende
- Centro Medico Luquez
-
Córdoba, Argentina, X5009BIN
- Aktiv, ikke rekrutterende
- Sanatorio Prof Leon S Morra S A
-
La Plata, Argentina, 1900
- Aktiv, ikke rekrutterende
- INSA Instituto de Neurociencias San Agustín
-
Rosario, Argentina, 2000
- Aktiv, ikke rekrutterende
- C I A P Centro de investigacion y Asistencia en Psiquiatria
-
Santiago del Estero, Argentina, 4200
- Aktiv, ikke rekrutterende
- Clinica El Jardin
-
-
-
-
-
Brasília, Brasilien, 70200 730
- Afsluttet
- L2IP Instituto de Pesquisas Clinicas
-
Campinas, Brasilien, 13087 567
- Aktiv, ikke rekrutterende
- CAEP Centro Avancado De Estudos E Pesquisas
-
Criciúma, Brasilien, 88811 000
- Aktiv, ikke rekrutterende
- Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
-
Natal, Brasilien, 59012 300
- Afsluttet
- Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
-
Passo Fundo, Brasilien, 99010 120
- Suspenderet
- Instituto Mederi de Pesquisa e Saude
-
Porto Alegre, Brasilien, 90619900
- Afsluttet
- Uniao Brasileira de Educacao e Assistencia INSCER Instituto do Cerebro do Rio Grande do Sul
-
Porto Alegre, Brasilien, 90035 903
- Afsluttet
- Hospital De Clinicas De Porto Alegre
-
Porto Alegre, Brasilien, 90430001
- Aktiv, ikke rekrutterende
- NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
-
Rio de Janeiro, Brasilien, 22270 060
- Aktiv, ikke rekrutterende
- Ruschel Medicina e Pesquisa Clínica Ltda
-
São Bernardo do Campo, Brasilien, 09726 150
- Aktiv, ikke rekrutterende
- Centro Integrado Facili
-
São Paulo, Brasilien, 01228 000
- Aktiv, ikke rekrutterende
- CPQuali Pesquisa Clinica LTDA ME
-
São Paulo, Brasilien, 01236030
- Aktiv, ikke rekrutterende
- BR Trials
-
-
-
-
-
Burgas, Bulgarien, 8001
- Aktiv, ikke rekrutterende
- Mental Health Center Prof. Dr. Ivan Temkov
-
Plovdiv, Bulgarien, 4002
- Aktiv, ikke rekrutterende
- UMHAT 'Sveti Georgi'- Plovdiv, Psychiatry Clinic
-
Sofia, Bulgarien, 1377
- Afsluttet
- Centre for Mental Health Prof.N.Shipkovenski EOOD
-
Sofia, Bulgarien, 1113
- Aktiv, ikke rekrutterende
- Medical Center St. Naum
-
Sofia, Bulgarien, 1408
- Aktiv, ikke rekrutterende
- DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
-
Stara Zagora, Bulgarien, 6010
- Afsluttet
- Medical Center ZaraMed
-
Varna, Bulgarien, 9020
- Aktiv, ikke rekrutterende
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Barranquilla, Colombia, 080002
- Aktiv, ikke rekrutterende
- Centro de Investigaciones y Proyectos en Neurociencias CIPNA
-
Bello, Colombia, 051053
- Aktiv, ikke rekrutterende
- HOMO - ESE Hospital Mental de Antioquia
-
Bogotá, Colombia, 111166
- Afsluttet
- Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
-
Pereira, Colombia, 660001
- Aktiv, ikke rekrutterende
- Psynapsis Salud Mental S.A.
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Afsluttet
- University of Alabama at Birmingham
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85224
- Afsluttet
- Chandler Clinical Trials
-
Tucson, Arizona, Forenede Stater, 85724
- Rekruttering
- University of Arizona
-
-
Arkansas
-
Bryant, Arkansas, Forenede Stater, 72022
- Rekruttering
- SanRo Clinical Research Group LLC WCG Clinical Network
-
Little Rock, Arkansas, Forenede Stater, 72211
- Afsluttet
- Preferred Research Partners
-
-
California
-
Anaheim, California, Forenede Stater, 92801
- Rekruttering
- PAMOJA Clinical Institute LLC
-
Colton, California, Forenede Stater, 92324
- Rekruttering
- Axiom Research
-
Encino, California, Forenede Stater, 91316
- Afsluttet
- Elite Research Network 6
-
Glendale, California, Forenede Stater, 91206
- Rekruttering
- Behavioral Research Specialists LLC
-
Los Alamitos, California, Forenede Stater, 90720
- Afsluttet
- WR PRI Los Alamitos
-
Oceanside, California, Forenede Stater, 92056
- Rekruttering
- Excell Research Inc
-
Rancho Cucamonga, California, Forenede Stater, 91730
- Afsluttet
- Prospective Research Innovations Inc
-
Redlands, California, Forenede Stater, 92374
- Rekruttering
- Anderson Clinical Research
-
San Jose, California, Forenede Stater, 95124
- Rekruttering
- Lumos Clinical Research Center LLC
-
Santa Ana, California, Forenede Stater, 92705
- Afsluttet
- Syrentis Clinical Research
-
Sherman Oaks, California, Forenede Stater, 91403
- Afsluttet
- California Neuroscience Research
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80209
- Rekruttering
- Mountain View Clinical Research
-
-
Connecticut
-
Farmington, Connecticut, Forenede Stater, 06030
- Rekruttering
- UConn Health Center
-
-
Florida
-
Brandon, Florida, Forenede Stater, 33511
- Rekruttering
- Clinical Research of Brandon
-
Hialeah, Florida, Forenede Stater, 33012
- Aktiv, ikke rekrutterende
- AGA Clinical Trials
-
Hialeah, Florida, Forenede Stater, 33012
- Aktiv, ikke rekrutterende
- Reliable Clinical Research
-
Homestead, Florida, Forenede Stater, 33033
- Aktiv, ikke rekrutterende
- Advanced Research Institute of Miami
-
Jacksonville, Florida, Forenede Stater, 32256
- Aktiv, ikke rekrutterende
- Clinical NeuroScience Solutions Inc
-
Lake City, Florida, Forenede Stater, 32055
- Afsluttet
- Multi Specialty Research Associates Inc
-
Largo, Florida, Forenede Stater, 33777
- Afsluttet
- Alcanza Clinical Research
-
Miami, Florida, Forenede Stater, 33186
- Rekruttering
- Nuovida Research Center
-
Miami, Florida, Forenede Stater, 33126
- Aktiv, ikke rekrutterende
- Pharmax Research Clinic Inc
-
Miami, Florida, Forenede Stater, 33176
- Aktiv, ikke rekrutterende
- Miami Dade Medical Research Institute
-
Naples, Florida, Forenede Stater, 34105
- Afsluttet
- Aqualane Clinical Research
-
North Bay Village, Florida, Forenede Stater, 33141
- Afsluttet
- Bravo Health Care Center
-
Orlando, Florida, Forenede Stater, 32803
- Aktiv, ikke rekrutterende
- Nova Psychiatry INC
-
Saint Augustine, Florida, Forenede Stater, 32086
- Afsluttet
- Florida Center for TMS
-
Tampa, Florida, Forenede Stater, 33613
- Afsluttet
- University of South Florida
-
Tampa, Florida, Forenede Stater, 33629
- Rekruttering
- Interventional Psychiatry of Tampa Bay
-
Tampa, Florida, Forenede Stater, 33614
- Rekruttering
- Psych Me Medical Research Inc
-
West Palm Beach, Florida, Forenede Stater, 33407
- Rekruttering
- Health Synergy Clinical Research
-
Winter Park, Florida, Forenede Stater, 32789
- Afsluttet
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Rekruttering
- Agile Clinical Research Trials, LLC
-
Atlanta, Georgia, Forenede Stater, 30318
- Aktiv, ikke rekrutterende
- Advanced Discovery Research
-
Decatur, Georgia, Forenede Stater, 30030
- Aktiv, ikke rekrutterende
- iResearch Atlanta LLC
-
Dunwoody, Georgia, Forenede Stater, 30338
- Afsluttet
- Peachford Hospital-Atlanta Behavorial Research
-
Savannah, Georgia, Forenede Stater, 31405
- Afsluttet
- iResearch Savannah
-
Snellville, Georgia, Forenede Stater, 30078
- Afsluttet
- Renew Health Clinical Research
-
Snellville, Georgia, Forenede Stater, 30078
- Afsluttet
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60614
- Afsluttet
- MetroMed Clinical Research
-
Chicago, Illinois, Forenede Stater, 60637
- Afsluttet
- University of Chicago Medical Center
-
Elgin, Illinois, Forenede Stater, 60123
- Afsluttet
- Revive Research Institute
-
Naperville, Illinois, Forenede Stater, 60563
- Rekruttering
- Baber Research Group
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02131
- Afsluttet
- Boston Clinical Trials
-
Watertown, Massachusetts, Forenede Stater, 02472
- Rekruttering
- Adams Clinical LLC
-
-
Minnesota
-
Mankato, Minnesota, Forenede Stater, 56001
- Afsluttet
- Mankato Clinic
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89121
- Afsluttet
- Oasis Clinical Research LLC
-
Las Vegas, Nevada, Forenede Stater, 89119
- Afsluttet
- Redbird Research
-
-
New Hampshire
-
Portsmouth, New Hampshire, Forenede Stater, 03801
- Afsluttet
- ActivMed Practices and Research
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11235
- Rekruttering
- SPRI Clinical Trials, LLC
-
Brooklyn, New York, Forenede Stater, 11229
- Rekruttering
- Integrative Clinical Trials LLC
-
Buffalo, New York, Forenede Stater, 14202
- Afsluttet
- University at Buffalo Psychiatry
-
Mount Kisco, New York, Forenede Stater, 10549
- Rekruttering
- Bioscience Research LLC
-
New York, New York, Forenede Stater, 10017
- Rekruttering
- Fieve Clinical Research Inc
-
New York, New York, Forenede Stater, 10022
- Afsluttet
- Hapworth Psychiatric Medical PLLC
-
Woodbury, New York, Forenede Stater, 11797
- Afsluttet
- Lucian Miron Manu MD Psychiatry PC
-
-
North Carolina
-
Hickory, North Carolina, Forenede Stater, 28601
- Afsluttet
- IMA Clinical Research PC 3
-
-
Ohio
-
Avon Lake, Ohio, Forenede Stater, 44012
- Afsluttet
- Haidar Almhana Nieding
-
Cincinnati, Ohio, Forenede Stater, 45215
- Rekruttering
- Patient Priority Clinical Sites LLC
-
Cincinnati, Ohio, Forenede Stater, 45219
- Afsluttet
- University of Cincinnati College of Medicine
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University
-
Middleburg Heights, Ohio, Forenede Stater, 44130
- Afsluttet
- North Star Medical Research
-
-
Oklahoma
-
Edmond, Oklahoma, Forenede Stater, 73013
- Rekruttering
- Conrad Clinical Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Afsluttet
- Medical University of South Carolina
-
Charleston, South Carolina, Forenede Stater, 29406
- Rekruttering
- Clinical Trials of South Carolina
-
-
Texas
-
Austin, Texas, Forenede Stater, 78712
- Afsluttet
- The University of Texas at Austin
-
Austin, Texas, Forenede Stater, 78759
- Afsluttet
- BioBehavioral Research of Austin PC
-
Bellaire, Texas, Forenede Stater, 77401
- Rekruttering
- Houston Clinical Trials LLC
-
Dallas, Texas, Forenede Stater, 75243
- Afsluttet
- Relaro Medical Trials
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- North Texas Clinical Trials
-
Garland, Texas, Forenede Stater, 75041
- Afsluttet
- VAST Clinical Research
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Houston, Texas, Forenede Stater, 77081
- Afsluttet
- DM Clinical Research
-
Stafford, Texas, Forenede Stater, 77477
- Aktiv, ikke rekrutterende
- R and H Clinical Research
-
Wichita Falls, Texas, Forenede Stater, 76309
- Rekruttering
- Grayline Research Center
-
-
Utah
-
Draper, Utah, Forenede Stater, 84020
- Afsluttet
- Cedar Clinical Research
-
-
Washington
-
Everett, Washington, Forenede Stater, 98201
- Rekruttering
- Core Clinical Research
-
-
-
-
-
Brescia, Italien, 25123
- Afsluttet
- Territorial Social Health Authority of the Spedali Civili of Brescia
-
Catania, Italien, 95123
- Aktiv, ikke rekrutterende
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Chieti, Italien, 66100
- Aktiv, ikke rekrutterende
- Universita D Annunzio
-
Genova, Italien, 16132
- Afsluttet
- IRCCS Aor San Martino IST
-
Monza, Italien, 20900
- Afsluttet
- Fondazione IRCCS San Gerardo dei Tintori
-
Pisa, Italien, 56126
- Afsluttet
- Azienda Ospedaliero Universitaria Pisana
-
Roma, Italien, 00168
- Afsluttet
- Policlinico Universitario Agostino Gemelli
-
Roma, Italien, 00189
- Aktiv, ikke rekrutterende
- Azienda Ospedaliera Sant Andrea
-
Salerno, Italien, 84020
- Afsluttet
- Ospedale S Francesco d Assisi
-
Siena, Italien, 53100
- Aktiv, ikke rekrutterende
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
-
-
-
-
Mexico City, Mexico, 04100
- Rekruttering
- Ketamine Mexico S de RL de C V
-
Mexico City, Mexico, 07000
- Rekruttering
- Gabipros SC
-
Mexico City, Mexico, 03100
- Afsluttet
- Health Pharma Professional Research
-
Monterrey, Mexico, 64710
- Rekruttering
- Instituto de Informacion e Investigacion en Salud Mental A.C.
-
Nuevo León, Mexico, 64460
- Rekruttering
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Nuevo León, Mexico, 64620
- Afsluttet
- Centro de Estudios Clinicos y Especialidades Medicas S C
-
San Luis de Potosi, Mexico, 78218
- Rekruttering
- Hospital Lomas de San Luis Internacional
-
-
-
-
-
Bydgoszcz, Polen, 85-133
- Rekruttering
- PROMENTE Sp. z o.o.
-
Bydgoszcz, Polen, 85 794
- Rekruttering
- Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
-
Bydgoszcz, Polen, 85 605
- Afsluttet
- Centrum Medyczne Intercor Sp z o o
-
Gdansk, Polen, 80 283
- Rekruttering
- Centrum Zdrowia Alcea
-
Gorlice, Polen, 30073
- Afsluttet
- Specjalistyczna Praktyka Lekarska Piotr Zalitacz
-
Grudziądz, Polen, 86 300
- Rekruttering
- Przychodnie Grudziadz sp. z o.o.
-
Katowice, Polen, 40 514
- Rekruttering
- Clinic BBP Sp z o o
-
Leszno, Polen, 64-100
- Rekruttering
- Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
-
Poznan, Polen, 60 192
- Rekruttering
- Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka
-
Warsaw, Polen, 00-774
- Rekruttering
- Szpital Nowowiejski Osrodek Badan Klinicznych
-
Warsaw, Polen, 02-172
- Afsluttet
- MTZ Clinical Research Powered by Pratia
-
-
-
-
-
Braga, Portugal, 4710 243
- Afsluttet
- Uls Braga - Hosp. Braga
-
Leiria, Portugal, 2410 197
- Afsluttet
- Uls Regiao Leiria - Hosp. Santo Andre
-
Lisbon, Portugal, 1649 035
- Afsluttet
- Uls Santa Maria - Hosp. Santa Maria
-
Lisbon, Portugal, 1349 019
- Afsluttet
- Uls Lisboa Ocidental - Hosp. Egas Moniz
-
Lisbon, Portugal, 1400 038
- Aktiv, ikke rekrutterende
- Fund. Champalimaud
-
Loures, Portugal, 2674 514
- Aktiv, ikke rekrutterende
- Uls Loures Odivelas - Hosp. Loures
-
Ponta Delgada, Portugal, 9500 370
- Afsluttet
- Hosp. Divino Espirito Santo Ponta Delgada
-
Porto, Portugal, 4100 180
- Aktiv, ikke rekrutterende
- Hosp. Cuf Porto
-
Touguinho, Portugal, 4480-565
- Afsluttet
- Hosp. Central Trofa Saude
-
-
-
-
-
Bucharest, Rumænien, 041914
- Rekruttering
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
-
Bucharest, Rumænien, 041914
- Afsluttet
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia 2
-
Cluj-Napoca, Rumænien, 400012
- Afsluttet
- Spitalul Clinic Judetean de Urgenta Cluj Napoca
-
Cluj-Napoca, Rumænien, 400012
- Afsluttet
- Spitalul Clinic Judetean de Urgenta Cluj Napoca 1
-
Craiova, Rumænien, 200157
- Rekruttering
- Centrul Medical Melchisedec
-
Focşani, Rumænien, 620117
- Afsluttet
- CMI Dr. Sarpe Marcel-Claudiu
-
Iași, Rumænien, 700282
- Afsluttet
- Institutului Regional de Psihiatrie 'Socola' Iasi
-
Iași, Rumænien, 700282
- Afsluttet
- Institutului Regional de Psihiatrie Socola Iasi 1
-
Iași, Rumænien, 700282
- Afsluttet
- Institutului Regional de Psihiatrie Socola Iasi 2
-
Oradea, Rumænien, 410169
- Rekruttering
- Spitalul Clinic Judetean de Urgenta Oradea
-
Sibiu, Rumænien, 550082
- Afsluttet
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
-
Sibiu, Rumænien, 550082
- Afsluttet
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda 1
-
Sânpetru, Rumænien, 507190
- Rekruttering
- Spitalul de Psihiatrie si Neurologie Brasov
-
-
-
-
-
Belgrade, Serbien, 11000
- Aktiv, ikke rekrutterende
- University Clinical Center of Serbia
-
Belgrade, Serbien, 11000
- Aktiv, ikke rekrutterende
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Gornja Toponica, Serbien, 18202
- Aktiv, ikke rekrutterende
- Special Hospital for Psychiatric Diseases Gornja Toponica
-
Kovin, Serbien, 26220
- Afsluttet
- Special Hospital for Psychiatric Diseases Kovin
-
Novi Kneževac, Serbien, 23330
- Afsluttet
- Specialized Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Bratislava, Slovakiet, 821 01
- Afsluttet
- Psychiatricka Ambulancia Mentum S.R.O.
-
Košice, Slovakiet, 040 01
- Rekruttering
- Univerzitna nemocnica L. Pasteura Kosice
-
Liptovský Mikuláš, Slovakiet, 031 23
- Rekruttering
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, Slovakiet, 979 01
- Rekruttering
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Svidník, Slovakiet, 089 01
- Rekruttering
- Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.
-
Vranov nad Topľou, Slovakiet, 093 01
- Rekruttering
- Crystal Comfort s.r.o.
-
-
-
-
-
Barcelona, Spanien, 08036
- Aktiv, ikke rekrutterende
- Hosp Clinic de Barcelona
-
Barcelona, Spanien, 8035
- Afsluttet
- Hosp Univ Vall D Hebron
-
Barcelona, Spanien, 08025
- Aktiv, ikke rekrutterende
- Institucion Hosp Hestia Palau
-
Bilbao, Spanien, 48013
- Afsluttet
- Hosp. Univ. de Basurto
-
Collado Villalba, Spanien, 28400
- Afsluttet
- Hosp. Gral. de Villalba
-
Madrid, Spanien, 28034
- Afsluttet
- Hospital Ramon y Cajal
-
Madrid, Spanien, 28031
- Aktiv, ikke rekrutterende
- Hosp. Univ. Infanta Leonor
-
Madrid, Spanien, 28046
- Aktiv, ikke rekrutterende
- Hosp. Univ. La Paz
-
Torrevieja, Spanien, 03186
- Afsluttet
- Hosp. Univ. de Torrevieja
-
-
-
-
-
Lund, Sverige, 22222
- Rekruttering
- ProbarE i Lund AB
-
Mölndal, Sverige, 43153
- Rekruttering
- CTC GoCo
-
Stockholm, Sverige, 114 37
- Rekruttering
- ProbarE i Stockholm AB
-
Uppsala, Sverige, 75237
- Rekruttering
- CTC MTC Uppsala
-
-
-
-
-
Brno, Tjekkiet, 61300
- Rekruttering
- Medipa S R O
-
Pilsen, Tjekkiet, 301 00
- Afsluttet
- A Shine S R O
-
Prague, Tjekkiet, 10000
- Rekruttering
- Clintrial s r o
-
Prague, Tjekkiet, 110 00
- Rekruttering
- Neuropsychiatrie Petrska sro
-
Prague, Tjekkiet, 16000
- Rekruttering
- Medical Services Prague S R O
-
Prague, Tjekkiet, 12000
- Afsluttet
- Pragtis S R O
-
-
-
-
-
Ankara, Tyrkiet (Türkiye), 06010
- Rekruttering
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara, Tyrkiet (Türkiye), 06800
- Afsluttet
- Ankara Bilkent Sehir Hastanesi
-
Ankara, Tyrkiet (Türkiye), 06620
- Afsluttet
- Ankara University Medical Faculty
-
Bursa, Tyrkiet (Türkiye), 16285
- Afsluttet
- Bursa High Speciality Training and Research Dortcelik Mental Hospital
-
Bursa, Tyrkiet (Türkiye), 16059
- Afsluttet
- Uludag Universitesi Tıp Fakultesi Hastanesi
-
Gaziantep, Tyrkiet (Türkiye), 27580
- Rekruttering
- Gaziantep Universitesi Tip Fakultesi
-
Istanbul, Tyrkiet (Türkiye), 34736
- Afsluttet
- Erenkoy Mental Hospital
-
Kocaeli, Tyrkiet (Türkiye), 41001
- Rekruttering
- Kocaeli University Medical Faculty
-
Samsun, Tyrkiet (Türkiye), 55020
- Rekruttering
- Liv Hospital
-
Trabzon, Tyrkiet (Türkiye), 61080
- Afsluttet
- Karadeniz Teknik University Medical Faculty
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Participants in part 1 and direct enrollers to part 2:
- Meet DSM-5 MDD, without psychotic features based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. An inadequate response is defined as less than (<) 50% reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ, and this must include the participant's current antidepressant treatment
- Is receiving and tolerating well any one of the following SSRI or SNRI for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks
- Having a major depressive episode of at least moderate severity, as assessed with 17-item Hamilton Depression Rating Scale, implemented through the Structured Interview Guide (SIGH-D) in a blinded manner at screening and must not demonstrate a clinically significant improvement from the beginning to end of screening.
Participants entering after completing part 1:
- Must have completed Part 1 DB treatment phase
- Can consistently tolerate study drug (at the end of Part 1), and there is no additional safety risk for the participant if they proceed to Part 2
- Was able to consistently follow the study procedures in Part 1 as judged by the investigator.
- Must be medically stable based on clinical laboratory tests
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of narcolepsy and seizures
- Has current signs/symptoms of hypothyroidism or hyperthyroidism
- Participants taking thyroid supplementation for antidepressant purposes
- Has Cushing's disease, Addison's disease, primary amenorrhea, or other evidence of significant medical disorders of the HPA axis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part 1: Seltorexant
Participants will receive seltorexant orally once daily for 6 weeks during the double-blind (DB) treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant throughout the study. |
Seltorexant will be administered orally.
Andre navne:
SSRI/SNRI will be administered orally. |
|
Placebo komparator: Part 1: Placebo
Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
|
Eksperimentel: Part 2: Open Label (OL) Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. In Part 2 open-label phases (induction and stabilization) all participants (newly enrolled direct entry participants and Part 1 roll-over participants) will receive seltorexant orally in addition to their background SSRI/SNRI treatment. |
Seltorexant will be administered orally.
Andre navne:
SSRI/SNRI will be administered orally. |
|
Eksperimentel: Part 2: DB Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phase will receive treatment with seltorexant orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
Seltorexant will be administered orally.
Andre navne:
SSRI/SNRI will be administered orally. |
|
Placebo komparator: Part 2: DB Placebo
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phases will receive treatment with matching placebo orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43
Tidsramme: Baseline, Day 43
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Response
Tidsramme: Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable response is defined as a greater than equal to (>=) 50 percent (%) reduction in the MADRS total score for the last 3 consecutive visits of the OL stabilization Phase, as assessed by the site investigator. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve a stable response at the end of OL seltorexant treatment will be reported. |
Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score at Day 43
Tidsramme: Baseline, Day 43
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score at Day 43
Tidsramme: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in the MADRS-6 Total Score at Day 43
Tidsramme: Baseline, Day 43
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of major depressive disorder (MDD) symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
Baseline, Day 43
|
|
Part 1: Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total score From Baseline to Day 43
Tidsramme: From Baseline to Day 43
|
Responders are defined as participants with >= 50 percent improvement in the MADRS total score from baseline to Day 43. |
From Baseline to Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (4a) T-score at Day 43
Tidsramme: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Tidsramme: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score at Day 43
Tidsramme: Baseline, Day 43
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Remission
Tidsramme: Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable remission is defined as MADRS total score less than or equal to (<=)10 and CGI-S <= 2 for at least 4 consecutive weeks of the OL stabilization Phase. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve stable remission at the end of the OL seltorexant treatment will be reported. |
Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (8a) T-Score
Tidsramme: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (4a) T-Score
Tidsramme: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
Tidsramme: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in MADRS Total Score
Tidsramme: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of DB Maintenance Phase in PHQ-9 Score
Tidsramme: From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
|
Change From Baseline to Endpoint of the DB Maintenance Phase in the MADRS-6 score
Tidsramme: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Change from Baseline to Endpoint of the DB Maintenance Phase in the MADRS symptoms other than insomnia MADRS Without Sleep Item (MADRS-WOSI)
Tidsramme: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trail, Janssen Research & Development, LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Stemningsforstyrrelser
- Depressiv lidelse
- Depressiv lidelse, major
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Neurotransmittermidler
- Membrantransportmodulatorer
- Neurotransmitter optagelseshæmmere
- Serotoninmidler
- Farmakologiske handlinger
- Kemiske handlinger og anvendelser
- Selektive Serotonin-genoptagelseshæmmere
- seltorexant
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 42847922MDD3003
- 42847922MDD3003 (Anden identifikator: Janssen Research & Development, LLC)
- 2023-509070-36-00 (Registry Identifier: EUCT number)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www janssen, com/clinical-trialsitransparency. As noted on this site, requests for access to the study data can be submitted through 'Yale Open Data Access (YODA) Project site at yoda yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .